Les résultats de l’étude clinique de phase I de l’anticorps bifonctionnel PD-1/CTLA-4 Iparomlimab/Tuvonralimab de Qilu Pharma, publiés en ligne dans le Journal of Hematology & Oncology USA – Français USA – English APAC – English USA – español USA – Deutsch
Rising Market Demand for High-Throughput Screening Bolsters Growth
Cryogenic Vials Market size to grow by USD 66.16 million from 2022 to 2027, North America to account for 36% of the market growth
Leading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote “FOR” Eight of Illumina’s Highly Qualified Director Nominees
Feedback from 153 Executives Across 92 Organizations from 37 Countries
America’s Best Wings: Everything You Need to Know
Covid-19: the government publishes the decree authorizing the return of non-vaccinated caregivers
40 years ago: the discovery of the AIDS virus
The AIDS epidemic in ten key dates
Four candidates from “Beijing Express” in the fight against cancer this Tuesday, May 16 in Auch
Cigarettes and vaping: how and why we make the same mistakes
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore.
